# A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

> **NCT03009344** · PHASE1 · COMPLETED · sponsor: **Eisai Co., Ltd.** · enrollment: 7 (actual)

## Conditions studied

- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT03009344
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-10
- **Primary completion:** 2017-07-12
- **Final completion:** 2020-06-17
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2022-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03009344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03009344, "A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03009344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*